Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
A phase 1/2 trial of HDP-101 in multiple myeloma, run by Heidelberg Pharma AG, now recruiting.
Overview
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT04879043 by Heidelberg Pharma AG, with 78 participants planned, started 2022-02-07 and due to reach its primary completion in 2028-03. Interventions recorded: HDP-101.
Similar pages
not linked directly; found by shared links- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.